Hengrui Pharmaceutical (600276.SH): HRS-4729 Injection Approved for Clinical Trials.

Zh tng cijng APP news, Hengrui Medicine (600276.SH) announced that recently, the company and its subsidiary, Fujian Shengdi Medicine Co., Ltd., received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration (referred to as the "National Medical Products Administration") for HRS-4729 injection solution. Clinical trials will be carried out in the near future.